Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.60 |
| ▸ | FPR2 | P25090 | 4/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30207638 | 0.95 | MEN1 (0.60) | MEN1BLMKMT2AUSP2POLB | |
| Hydrochloric Acid SCHEMBL18617 | 0.95 | MEN1 (0.60) | MEN1BLMKMT2AUSP2POLB | |
| Hydrochloric Acid SCHEMBL29354092 | 0.95 | MEN1 (0.60) | MEN1BLMKMT2AUSP2POLB | |
| Hydrochloric Acid SCHEMBL10325011 | 0.94 | MEN1 (0.59) | MEN1BLMKMT2AUSP2POLB | |
| Hydrochloric Acid SCHEMBL31337069 | 0.94 | MEN1 (0.59) | MEN1BLMKMT2AUSP2POLB | |
| SCHEMBL29593395 | 0.94 | MEN1 (0.61) | MEN1BLMKMT2AUSP2POLB | |
| SCHEMBL3903552 | 0.94 | MEN1 (0.61) | MEN1BLMKMT2AUSP2POLB | |
| Perchlorate SCHEMBL31688153 | 0.91 | MEN1 (0.60) | MEN1BLMKMT2AUSP2POLB | |
| Acetic Acid SCHEMBL29510237 | 0.91 | MEN1 (0.60) | MEN1BLMKMT2AUSP2POLB | |
| Piperazine SCHEMBL1317991 | 0.90 | MEN1 (0.55) | MEN1BLMKMT2AUSP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9731035-B2 | Method of imaging osteoarthritis using a folate conjugate | PURDUE RESEARCH FOUNDATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-1904183-B1 | Pharmaceutical composition for the treatment of osteoarthritis | PURDUE RESEARCH FOUNDATION (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140065066-A1 | IMAGING AND THERAPEUTIC METHOD USING MONOCYTES | PURDUE RESEARCH FOUNDATION (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130266964-A1 | METHOD OF DETECTING ENDOTHELIAL PROGENITOR CELLS | PURDUE RESEARCH FOUNDATION (US) | 2013-10-10 | — | — | US | disclosed |
| US-20100226967-A1 | IMAGING AND THERAPEUTIC METHOD USING PROGENITOR CELLS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-09 | — | — | US | disclosed |
| EP-1904183-A2 | IMAGING AND THERAPEUTIC METHOD USING MONOCYTES | Purdue Research Foundation (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007139815-A2 | IMAGING AND THERAPEUTIC METHOD USING PROGENITOR CELLS | PURDUE RESEARCH FOUNDATION (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070009434-A1 | Imaging and therapeutic method using monocytes | PURDUE RESEARCH FOUNDATION | 2007-01-11 | — | — | US | disclosed |
| WO-2007006041-A2 | IMAGING AND THERAPEUTIC METHOD USING MONOCYTES | PURDUE RESEARCH FOUNDATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226967-A1 | IMAGING AND THERAPEUTIC METHOD USING PROGENITOR CELLS | CD44, MYADM, ANTXR2 | CHRM1 3500/4885MEN1 1317/4885BLM 1339/4885 |
| US-20070009434-A1 | Imaging and therapeutic method using monocytes | CD14, MYADM, CD68 | CHRM1 1303/4885MEN1 860/4885BLM 930/4885 |
| US-20140065066-A1 | IMAGING AND THERAPEUTIC METHOD USING MONOCYTES | CD14, MYADM, CD68 | CHRM1 1303/4885MEN1 860/4885BLM 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.